Novo Nordisk’s semaglutide cuts kidney disease progression in trial
Based on FLOW data, Novo Nordisk plans to seek regulatory approval for expanding Ozempic's label in the US and EU this year.
06 March 2024
06 March 2024
Based on FLOW data, Novo Nordisk plans to seek regulatory approval for expanding Ozempic's label in the US and EU this year.
A new study suggests that Japanese patients with chronic conditions score lower than other developed countries across a range of metrics.
The study, published in the Journal of Medical Imaging, found that MediView’s augmented reality system for guiding ultrasound needles has a high rate of accuracy.
In the trial, four partial responses and one complete response were reported among eight evaluable subjects.
The first two parts of the trial will evaluate a single intracerebroventricular infusion of GS-100 in patients aged two to 18 years old.
The company aims to commence subject enrolment soon to establish the safety profile of the vaccine.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.